Queensland Life Sciences Industry Report 2012 (PDF, 3.5MB)

considered ‘microcap’ — with a market cap of less than $50
million. As at 30 June 2011, only three of eight companies were
‘microcap’. All but one of the companies that were listed in both
2009 and 2011 increased their market cap during this period
(Table 47).
TABLE 47: Market capitalisation of ASX-Listed Queensland Life
Sciences companies 78
Company Code Life Sciences
Sub-sector
Alchemia
Limited
ACL Pharma,
vaccines or
drug discovery
Analytica Limited ALT Medical devices
and equipment
Anteo
Diagnostics
(previously
Bio-Layer)
BioProspect
Limited
ADO Pharma,
vaccines or
drug discovery
CBio Limited CBZ Pharma,
vaccines
or drug
discovery
Impedimed
Limited
Progen
Pharmaceuticals
Ltd
Market Cap ($m)
2009* 2011 + Change
$57.0 $117.0 105%
$7.5 $12.3 64%
$1.8 $53.4 2867%
BPO Biotechnology $8.3 $8.9 8%
IPD Medical devices
and equipment
PGL Pharma
vaccines or
drug discovery
N/A $98.2 N/A
$62.3 $89.2 43%
$21.0 $5.7 -73%
Tissue Therapies TIS Biotechnology $12.5 $97.0 676%
* As at 30 June 2009 + As at 30 June, 2011
8.3 Market Capitalisation — Queensland, Australia,
New Zealand and Canada
Figure 22 shows the average market cap of Queensland and
Australian listed Life Sciences firms, as at 30 June 2011. The
average market cap of the non-major Australian Life Sciences
firms on the ASX (i.e. excluding CSL, RMD and COH) was $91.7
million. For the Queensland based firms, the average market
cap was approximately one third lower at $60.2 million.
Figure 22: Average market capitalisation of ASX-listed Life
Sciences firms, Queensland vs. Australia, 30 June 2011
The average market cap of the non-majors and the listed
Queensland firms dropped below 2007 levels during 2008
and 2009, a period which coincides with the GFC (2008-2009)
(Figure 23). The average market cap for Australian and Queensland
listed firms grew in both 2010 and 2011. 79
Figure 23: Average market capitalisation of ASX-listed Life
Sciences firms, Queensland vs. Australia, at Q4 2007-2011
To put the listed market cap figures into some perspective, the
Queensland and Australian averages were compared to those for
New Zealand and Canada.
In some respects, the New Zealand Life Sciences sector provides
a useful comparator for Queensland. Both regions have a similar
population base (Queensland 4,580,282 80 ; New Zealand
4,407,500 81 ) and a similar number of resident Life Sciences
78 Market capitalisation data sourced from PwC BioForum Edition 36, Quarter 4 FY11, August 2011.
79 Market capitalisation data sourced from PwC Quarterly BioForum Publications Q4, 2007, PwC BioForum, Edition 25, Quarter 4 FY08, August 2008, PwC BioForum,
Edition 29, Quarter 4 FY09, August 2009, PwC BioForum, Edition 33, Quarter 4 FY10/Quarter 1 FY11, November 2010, Edition 36, Quarter 4 FY11, August 2011.
80 Queensland Government Office of Economic and Statistical Research, http://www.oesr.qld.gov.au/products/tables/erp-lga-reformed-qld/index.php. (30 June 2011).
81 New Zealand Government, Statistics New Zealand, Population Indicators, http://www.stats.govt.nz/browse_for_stats/population/estimates_and_projections/popindicators.aspx
53